Go Pro
TSE:SVA

Sernova Q1 2026 Earnings Report

Sernova logo
C$0.13 0.00 (0.00%)
As of 07/3/2026 03:57 PM Eastern

Sernova EPS Results

Actual EPS
C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, March 18, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Sernova Earnings Headlines

Stocks in play: Sernova Biotherapeutics Inc.
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Off-market insider buying at Sernova Biotherapeutics (SVA)
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

View Sernova Profile